KLRD1 and hypoparathyroidism-retardation-dysmorphism syndrome: α,α′-diethyl-3,4,4′-stilbenetriol showed a significant negative correlation with KLRD1 expression (p < 0.05) (Figure 6E), suggesting that both may contribute critically to the therapeutic effects of Sal B in the context of HRD.